DBP International AB: Pharmacokinetic study of SI-053 in animals is completed
Double Bond Pharmaceutical International AB (publ) ("DBP", "Double Bond" or "Double Bond Pharmaceutical") announces positive results from its SI-053 in vivo pharmacokinetic study in rats. SI-053 is Double Bond’s front-line product for local therapy of primary malignancies in the brain. In accordance with the recommendations from the European Agency of Medicines (EMA), DBP has evaluated the local and systemic distribution of temozolomide (TMZ) in the brain, cerebrospinal fluid (CSF) and plasma, and its metabolites after intracerebral injection of SI-053 in rats. The results showed that